Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
Think_Bigly
Think_Bigly Jul. 28 at 10:52 PM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Jul. 28 at 9:40 PM
$AFMD as of today, this is where they stand: https://www.affimed.com/about-us/partners/
0 · Reply
Morseus01
Morseus01 Jul. 28 at 5:59 PM
$AFMD finally hit onto sell only on all the brokers I use I guess now is the waiting game to see if it ever goes back up no more buy orders
0 · Reply
Think_Bigly
Think_Bigly Jul. 25 at 12:10 AM
$AFMD do you think Gilde would put another $12 into this to rescue the 1st $12? Or how about Roche puts another $150M in to eliminate the certainty of $2.5B royalties on such golden data? Probably both would. The data has never been more valuable.
0 · Reply
deathknight
deathknight Jul. 24 at 1:50 AM
$AFMD just found out that they terminated AFM28 trail. The other two are still recruiting. It seems to be a decision made late last year but they probably waited several months to collect more safety/efficacy data. Not sure if it's good or bad sign but they are very much alive on clinical trials and keep on managing them.
2 · Reply
13Tpro
13Tpro Jul. 23 at 3:44 PM
$AFMD At IB I am only able to sell the stock. At which broker can you still buy it, anyone?
2 · Reply
Think_Bigly
Think_Bigly Jul. 22 at 9:46 PM
$AFMD on Nature - A vast pipeline of opportunities - Affimed has cleared the investigational new drug (IND) stage and is now initiating a clinical trial of AFM24 in patients with tumors known to express EGFR, putting it on a path that could lead to approvals in multiple underserved populations. AFM24 is advancing in parallel with AFM13, which is closing in on an interim analysis of its registration-directed study and the initiation of other trials. The clinical-phase assets are the tip of a vast pipeline of opportunities enabled by the ROCK platform. Affimed has further preclinical programs (AFM26, AFM28 and AFM32) and the ability to create new ICEs using the modular ROCK platform, equipping it to partner from drug discovery through to late-phase development. Affimed is seeking commercial and development partners for the lead clinical-phase assets and is exploring partnerships to accelerate and expand preclinical development.
0 · Reply
deathknight
deathknight Jul. 22 at 4:05 PM
$AFMD it's the first I have ever seen a stressed/bankrupt company stay in a complete PR black out this long... Can they just give us any update at all?
2 · Reply
Supplement
Supplement Jul. 21 at 2:05 PM
$ARTV Still no news but I have a feeling it has something to do with $AFMD affimed's insolvency.
1 · Reply
Think_Bigly
Think_Bigly Jul. 19 at 7:43 PM
$AFMD Genentech, a member of the Roche Group, has committed up to $5 billion in potential milestone payments and royalties to generate candidates through Affimed's ROCK platform .. as well as MULTIPLE undisclosed solid and hematologic tumor targets. $8-$16. https://www.genengnews.com/news/genentech-affimed-launch-up-to-5b-cancer-immunotherapy-collaboration/
0 · Reply
Latest News on AFMD
No data available.
Think_Bigly
Think_Bigly Jul. 28 at 10:52 PM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Jul. 28 at 9:40 PM
$AFMD as of today, this is where they stand: https://www.affimed.com/about-us/partners/
0 · Reply
Morseus01
Morseus01 Jul. 28 at 5:59 PM
$AFMD finally hit onto sell only on all the brokers I use I guess now is the waiting game to see if it ever goes back up no more buy orders
0 · Reply
Think_Bigly
Think_Bigly Jul. 25 at 12:10 AM
$AFMD do you think Gilde would put another $12 into this to rescue the 1st $12? Or how about Roche puts another $150M in to eliminate the certainty of $2.5B royalties on such golden data? Probably both would. The data has never been more valuable.
0 · Reply
deathknight
deathknight Jul. 24 at 1:50 AM
$AFMD just found out that they terminated AFM28 trail. The other two are still recruiting. It seems to be a decision made late last year but they probably waited several months to collect more safety/efficacy data. Not sure if it's good or bad sign but they are very much alive on clinical trials and keep on managing them.
2 · Reply
13Tpro
13Tpro Jul. 23 at 3:44 PM
$AFMD At IB I am only able to sell the stock. At which broker can you still buy it, anyone?
2 · Reply
Think_Bigly
Think_Bigly Jul. 22 at 9:46 PM
$AFMD on Nature - A vast pipeline of opportunities - Affimed has cleared the investigational new drug (IND) stage and is now initiating a clinical trial of AFM24 in patients with tumors known to express EGFR, putting it on a path that could lead to approvals in multiple underserved populations. AFM24 is advancing in parallel with AFM13, which is closing in on an interim analysis of its registration-directed study and the initiation of other trials. The clinical-phase assets are the tip of a vast pipeline of opportunities enabled by the ROCK platform. Affimed has further preclinical programs (AFM26, AFM28 and AFM32) and the ability to create new ICEs using the modular ROCK platform, equipping it to partner from drug discovery through to late-phase development. Affimed is seeking commercial and development partners for the lead clinical-phase assets and is exploring partnerships to accelerate and expand preclinical development.
0 · Reply
deathknight
deathknight Jul. 22 at 4:05 PM
$AFMD it's the first I have ever seen a stressed/bankrupt company stay in a complete PR black out this long... Can they just give us any update at all?
2 · Reply
Supplement
Supplement Jul. 21 at 2:05 PM
$ARTV Still no news but I have a feeling it has something to do with $AFMD affimed's insolvency.
1 · Reply
Think_Bigly
Think_Bigly Jul. 19 at 7:43 PM
$AFMD Genentech, a member of the Roche Group, has committed up to $5 billion in potential milestone payments and royalties to generate candidates through Affimed's ROCK platform .. as well as MULTIPLE undisclosed solid and hematologic tumor targets. $8-$16. https://www.genengnews.com/news/genentech-affimed-launch-up-to-5b-cancer-immunotherapy-collaboration/
0 · Reply
Think_Bigly
Think_Bigly Jul. 18 at 1:39 AM
And the cost of the $AFMD platform is down ~90% from the $4.9B Roche initially offered in milestones and partner pymts.. With 'transformational data in patients suffering from end-stage Hodgkin’s lymphoma' .. as well as very positive data in end-stage lung cancer. And NO royalties in a buyout.
0 · Reply
Think_Bigly
Think_Bigly Jul. 17 at 7:24 PM
$AFMD Expert Markets https://www.sec.gov/newsroom/press-releases/2020-212 FACT SHEET Publication or Submission of Quotations Without Specified Information Amendments Rule 15c2-11 (the "Rule") governs the publication or submission of quotations by broker-dealers in a quotation medium other than a national securities exchange. Before a broker-dealer may initiate or resume quotations for a security in a quotation medium, the broker-dealer must review key, basic information about the issuer of the security. The Rule allows any qualified interdealer quotation system (“qualified IDQS”) to conduct the required information review as well.
0 · Reply
Slambucket
Slambucket Jul. 17 at 10:16 AM
$AFMD - This security is now traded on the Expert Market The Expert Market® serves broker-dealer pricing and investor best execution needs. Quotations in Expert Market securities are restricted from public viewing. OTC Markets Group may designate securities for quoting on the Expert Market when it is not able to confirm that the company is making current information publicly available under SEC Rule 15c2-11, or when the security is otherwise restricted from public quoting.
2 · Reply
Think_Bigly
Think_Bigly Jul. 16 at 12:54 AM
$AFMD -ht DT Affimed is developing a product pipeline consisting of three clinical-stage drug candidates, providing the company with one of the most mature pipelines in the innate immune oncology field. The company’s lead product candidate has demonstrated transformational data in patients suffering from end-stage Hodgkin’s lymphoma. If these results can be replicated, Affimed has the potential to lead a paradigm shift in oncology by offering a life-changing new treatment option for thousands of patients. -In addition, Affimed’s second product candidate has shown very promising data in end-stage lung cancer patients, a group that is rapidly growing and for which treatment options are virtually non-existent.
0 · Reply
deathknight
deathknight Jul. 15 at 7:24 PM
$AFMD Almost a dead space. I will just leave this here, in case anyone's interested in institutional holdings of the company: https://gildehealthcare.com/portfolio/venture-and-growth/affimed/. They paid $102M in 2022 for 8m shares and filed a 13G for the transaction. They haven't filed anything about AFMD since then -- I take this means that they still hold their shares or potentially added more. They'd need to file another 13G if they sold to below the 5% threshold (they were at 5.6%).
0 · Reply
Think_Bigly
Think_Bigly Jul. 14 at 2:31 AM
$AFMD Roche really wants this.. -'There have only been a few deals(3) in the past that have amounted to a $5 billion milestone payment for a biotech. What that tells me is that Roche really wants to get its hands on Affimed’s Redirected Optimized Cell Killing (ROCK) platform.' What they don't really want is 12 yrs of this.. 'This is a total of $4.9 billion, and also includes tiered royalties.' Which will add billions more. Ownership ends royalties. https://www.biospace.com/affimed-stock-more-than-doubles-after-4-9-billion-deal-with-roche
0 · Reply
Think_Bigly
Think_Bigly Jul. 13 at 10:25 PM
$AFMD Even Merck is in on this: Affimed Trials AFM13 with Keytruda Affimed N.V. (AFMD) announced a Phase 1b clinical trial evaluating AFM13 in combination with Merck & Co.'s (MRK) KEYTRUDA (pembrolizumab) for patients with Hodgkin lymphoma. Phase 1b Clinical Trial: The trial investigated the combination of AFM13, a bispecific antibody targeting CD30 and CD16A, with KEYTRUDA, an anti-PD-1 therapy, for patients with relapsed or refractory Hodgkin lymphoma. Preclinical Synergy: Preclinical studies demonstrated that AFM13, in combination with an anti-PD-1 antibody, showed significant synergy, with up to 90% of tumors eradicated in patient-derived xenograft models. Publication of Results: The Phase 1b study results were published in Blood, showing an objective response rate (ORR) of 88% at the highest treatment dose, with a complete response (CR) rate of 46%.
0 · Reply
Think_Bigly
Think_Bigly Jul. 13 at 1:52 AM
$AFMD "$4.9 billion in milestones and royalties." are written in stone. -Roche would pay some ~8.5% royalties on the www.affimed.com/pipeline/.. for 11-12 years. Or.. imo.. collect them. -The global lymphoma(blood) treatment market size was valued at USD 7.41 billion in 2024 and is anticipated to grow at a CAGR of 8.3%(Bigly) from 2025 to 2030. -The solid tumor cancer treatment market size has grown rapidly in recent years. It will grow from $232.2 billion in 2024 to $266.16 billion in 2025 at a compound annual growth rate (CAGR) of 14.6%. The growth -advancements in research and development, drug development and approvals, increased cancer incidence rates.. -The global acute(liquid) myeloid leukemia treatment market is expected to grow from USD 3.14 billion in 2025 to USD 6.85 billion by 2033, with a CAGR of 10.25% during the forecast period. - You can bet your @ss, Roche will be there to collect their share. EOS.
0 · Reply
Think_Bigly
Think_Bigly Jul. 11 at 8:58 PM
$AFMD M & A will explode.. - “I’m encouraged by reports that Jerome Powell is considering resigning. I think this will be the right decision for America, and the economy will boom,” Pulte said.
1 · Reply
Think_Bigly
Think_Bigly Jul. 11 at 7:51 PM
$AFMD "Once a candidate advances beyond late-stage research, Genentech will take sole control and guide it through clinical development and, potentially, commercialization. As it does so, the Roche subsidiary will hand over a growing slice of the $5 billion in milestones and royalties."
0 · Reply
Think_Bigly
Think_Bigly Jul. 11 at 7:14 PM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Jul. 11 at 6:56 PM
$AFMD Roche saw this coming almost a year ago. They've seen it 50x. They're not giving up $100M and 5 years of great data. So, 919M shares traded up 5/16, 3 days after the filing... says employees and friends bought. https://www.fiercebiotech.com/biotech/affimed-lands-big-backloaded-immunotherapy-deal-genentech-sending-its-stock-into-overdrive
1 · Reply